Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 13/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2787680 | 0.83 | LPL (0.45) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL2427419 | 0.83 | LPL (0.47) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL12502043 | 0.81 | LPL (0.43) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL239104 | 0.80 | LPL (0.56) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL29986688 | 0.80 | CA1 (0.48) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL2635766 | 0.80 | CA1 (0.51) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL30124283 | 0.80 | CA1 (0.51) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL5429666 | 0.80 | CA1 (0.48) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL19495527 | 0.80 | LPL (0.45) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL5899542 | 0.80 | CA1 (0.51) | LPLLIPGCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4001277-A2 | BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY | AC Immune SA (CH) | 2022-05-25 | — | — | EP | disclosed |
| EP-3426653-B1 | BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY | AC IMMUNE SA (CH) | 2021-12-15 | — | — | EP | disclosed |
| US-20200299305-A1 | BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY | AC IMMUNE SA | 2020-09-24 | — | — | US | disclosed |
| US-20190071450-A1 | BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY | AC IMMUNE SA (CH) | 2019-03-07 | — | — | US | disclosed |
| EP-2718293-B1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | HUTCHISON MEDIPHARMA LTD (CN) | 2017-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071450-A1 | BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY | SNCA, PARK7, NLN | LPL 3756/4885LIPG 4523/4885CA1 3173/4885 |
| US-20200299305-A1 | BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY | SNCA, PARK7, NLN | LPL 3756/4885LIPG 4523/4885CA1 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.